Hosted on MSN2h
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...
Hedge Fund Citadel takes short position in GSK, FT reports
Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on ...
GSK shares shorted by leading U.S. hedge fund, The Times reports
The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...
GlaxoSmithKline Pharma Q3 results: Net profit up five-fold at Rs 229 crore
GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.
money.rediff7h
GlaxoSmithKline Q3 Profit Surges 5x to Rs 229 cr - Business News
GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...
GSK Q3FY25 Results: Net profit jumps 4X to ₹229 crore; revenue improves 18%
GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...
The Financial Express9h
Q3FY25: GSK pharma’s profit surges 4X to Rs 229 crore; Revenue up 18 percent
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
cnbctv1810h
GSK Pharma Q3 Results: Strong revenue, EBITDA growth; vaccines segment gains
GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...
Bright Outlook for Nabtesco, on the Secular Demand for Automation and Construction Equipment
The company is well positioned for a secular growth of industrial robot demand, driven by skilled labor shortage and need to increase production efficiency through automation. We expect the company's ...